Suppr超能文献

肺靶向性肌浆网Ca2+-ATP酶2a基因治疗：从发现到在博来霉素诱导的肺纤维化中的治疗应用

Lung-targeted SERCA2a Gene Therapy: From Discovery to Therapeutic Application in Bleomycin-Induced Pulmonary Fibrosis.

作者信息

Bisserier Malik, Hadri Lahouaria

机构信息

Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

出版信息

J Cell Immunol. 2020;2(4):149-156. Epub 2020 May 6.

PMID:32587955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7316402/
Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by an accumulation of scar tissue within the lungs and the common presence of usual interstitial pneumonia. Unfortunately, only a few FDA-approved therapeutic options are currently available for the treatment of IPF and IPF remains associated with poor prognosis. Therefore, the identification of new pharmacological targets and strategies are critical for the treatment of IPF. This commentary aims to further discuss the role of sarcoplasmic reticulum Ca-ATPase 2a and its downstream signaling in IPF. Finally, this commentary offers new insights and perspectives regarding the therapeutic potential of AAV-mediated SERCA2A gene therapy as an emerging therapy for respiratory diseases.

摘要

特发性肺纤维化（IPF）是一种间质性肺疾病，其特征是肺部瘢痕组织积聚以及普通型间质性肺炎普遍存在。不幸的是，目前FDA批准的用于治疗IPF的治疗选择很少，且IPF的预后仍然很差。因此，确定新的药理学靶点和策略对于IPF的治疗至关重要。本评论旨在进一步探讨肌浆网Ca-ATP酶2a及其下游信号在IPF中的作用。最后，本评论就腺相关病毒介导的SERCA2A基因治疗作为一种新兴的呼吸系统疾病治疗方法的治疗潜力提供了新的见解和观点。

相似文献

1
Lung-targeted SERCA2a Gene Therapy: From Discovery to Therapeutic Application in Bleomycin-Induced Pulmonary Fibrosis.
J Cell Immunol. 2020;2(4):149-156. Epub 2020 May 6.
2
The Chemokine System as a Key Regulator of Pulmonary Fibrosis: Converging Pathways in Human Idiopathic Pulmonary Fibrosis (IPF) and the Bleomycin-Induced Lung Fibrosis Model in Mice.
Cells. 2024 Dec 12;13(24):2058. doi: 10.3390/cells13242058.
3
AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.
Mol Ther. 2020 Feb 5;28(2):394-410. doi: 10.1016/j.ymthe.2019.11.027. Epub 2019 Dec 6.
4
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Int J Mol Sci. 2021 Aug 24;22(17):9105. doi: 10.3390/ijms22179105.
5
The Bleomycin Model of Pulmonary Fibrosis.
Methods Mol Biol. 2017;1627:27-42. doi: 10.1007/978-1-4939-7113-8_2.
6
Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients.
Cells. 2024 Dec 12;13(24):2050. doi: 10.3390/cells13242050.
7
USP7 Promotes TGF-β1 Signaling by De-Ubiquitinating Smad2/Smad3 in Pulmonary Fibrosis.
Discov Med. 2024 Aug;36(187):1616-1626. doi: 10.24976/Discov.Med.202436187.148.
8
Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.
J Am Coll Cardiol. 2016 May 3;67(17):2032-46. doi: 10.1016/j.jacc.2016.02.049.
9
Xuanfei Baidu decoction ameliorates bleomycin-elicited idiopathic pulmonary fibrosis in mice by regulating the lung-gut crosstalk via IFNγ/STAT1/STAT3 axis.
Phytomedicine. 2024 Dec;135:155997. doi: 10.1016/j.phymed.2024.155997. Epub 2024 Sep 2.
10
Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.
Circulation. 2013 Jul 30;128(5):512-23. doi: 10.1161/CIRCULATIONAHA.113.001585. Epub 2013 Jun 26.

引用本文的文献

1
Progress in Respiratory Gene Therapy.
Hum Gene Ther. 2022 Sep;33(17-18):893-912. doi: 10.1089/hum.2022.172.
2
Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases.
Cells. 2022 Mar 12;11(6):984. doi: 10.3390/cells11060984.
3
Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Int J Mol Sci. 2021 Aug 24;22(17):9105. doi: 10.3390/ijms22179105.

本文引用的文献

1
Del-1, an Endogenous Inhibitor of TGF-β Activation, Attenuates Fibrosis.
Front Immunol. 2020 Feb 7;11:68. doi: 10.3389/fimmu.2020.00068. eCollection 2020.
2
The deubiquitinase OTUB1 augments NF-κB-dependent immune responses in dendritic cells in infection and inflammation by stabilizing UBC13.
Cell Mol Immunol. 2021 Jun;18(6):1512-1527. doi: 10.1038/s41423-020-0362-6. Epub 2020 Feb 5.
3
AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.
Mol Ther. 2020 Feb 5;28(2):394-410. doi: 10.1016/j.ymthe.2019.11.027. Epub 2019 Dec 6.
4
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
Respir Res. 2019 Sep 6;20(1):205. doi: 10.1186/s12931-019-1161-4.
5
Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension.
J Mol Cell Cardiol. 2019 Feb;127:20-30. doi: 10.1016/j.yjmcc.2018.11.017. Epub 2018 Nov 28.
6
Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes.
Med Sci (Basel). 2018 Nov 29;6(4):110. doi: 10.3390/medsci6040110.
7
Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension.
Pulm Circ. 2018 Oct-Dec;8(4):2045894018799738. doi: 10.1177/2045894018799738. Epub 2018 Aug 21.
8
Transcriptional cofactors Ski and SnoN are major regulators of the TGF-β/Smad signaling pathway in health and disease.
Signal Transduct Target Ther. 2018 Jun 8;3:15. doi: 10.1038/s41392-018-0015-8. eCollection 2018.
9
FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis.
J Clin Invest. 2018 Jun 1;128(6):2389-2405. doi: 10.1172/JCI87631. Epub 2018 May 7.
10
Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis.
Front Med (Lausanne). 2017 Jul 28;4:118. doi: 10.3389/fmed.2017.00118. eCollection 2017.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验